There are several opportunities in the hospital sector.
Due to rising healthcare spending by developing nations and the availability of highly developed and sophisticated healthcare infrastructure in developed countries, the hospital sector will have the biggest market share for nuclear medicine equipment from 2022 to 2032. Additionally, the target patient population has grown, and hospitals all over the world now need to identify and treat patients earlier due to the growth in lifestyle diseases like cancer and cardiovascular disease.
Governmental and corporate organisations have boosted their investment in research centres as a result of the rise in lifestyle disorders, making this the fastest-growing industry with a CAGR of 4.8%. The demand for nuclear medical technology is rising.
Report Summary
The size of the worldwide nuclear medicine market was assessed to be USD 8.1 billion in 2021, and it is anticipated to increase at a CAGR of 13.0% from 2022 to 2030. The market is expanding as a result of a strong product pipeline and supportive government programmes to expand access to nuclear medicine. Currently, a number of products are undergoing clinical trials, including betalutin, omburtamab, yttrium-90 microspheres, PNT2003, and 177Lu-PNT2002. The SARS-CoV-2 virus has had a minor negative influence on the nuclear medicine sector. Given its criticality, operating reactors has often been categorised as an essential service. Therefore, during the SARS-CoV-2 shutdown, nuclear reactors were not shut down. For instance, in South Africa, under Section 71 of the Labour Act 66 of 1995,
Additionally, as its reactor produces essential medications, it continued to operate throughout the COVID-19 crisis, with its workers returning to campus and adhering to stringent social distancing rules, according to an article published by ANSTO in May 2020. The American Cancer Society estimates that there will be around 34,500 prostate cancer deaths in the United States in 2022, with a prostate cancer incidence of 268.490. Additionally, 6 out of 10 patients with a diagnosis are men 65 years of age and older, with men under 40 years of age having a very low frequency. Pluvicto (177Lu-PSMA-617) was just given FDA approval in March 2022 for the treatment of patients with metastatic prostate cancer. It is believed that this approval will encourage market expansion.
For More Insights Download Sample: https://analyticsmarketresearch.com/sample-request/nuclear-medicine-equipment-market/24661/
Global Nuclear Medicine Equipment Market: Major Players
Digirad Corporation
DDD- Diagnostics A/S
Neusoft Corporation
Siemens Aktiengesellschaft
Mediso Medical Imaging Systems, Ltd
Bozlu Holding
SurgicEye GmbH
General Electric Company
Koninklijke Philips N.V.
Toshiba Corporation
Compañía Mexicana de Radiología CGR, S.A de C.V.
Global Nuclear Medicine Equipment Market: By Types
Single-Photon Emission Computed Tomography (SPECT)
Positron Emission Tomography (PET)
Global Nuclear Medicine Equipment Market: By Applications
Hospitals
Imaging Centers
Academic & Research Institutes
Click Here for Direct Purchase Nuclear Medicine Equipment Market Research Report:
Global Nuclear Medicine Equipment Market: Regional Analysis
All the regional segmentation has been studied based on recent and future trends, and the market is forecasted throughout the prediction period. The countries covered in the regional analysis of the Global Nuclear Medicine Equipment market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Russia, Italy, Spain, Turkey, Netherlands, Switzerland, Belgium, and Rest of Europe in Europe, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, China, Japan, India, South Korea, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), and Argentina, Brazil, and Rest of South America as part of South America.
Application Perspectives
Global nuclear medicine is segmented into cancer, thyroid, neurology, cardiology, lymphoma, bone metastasis, endocrine tumours, and other markets based on application. In 2021, the oncology category held the majority of the market. One of the main causes of death in the globe is cancer. The prevalence of some conditions is on the rise as a result of factors like poor diet, smoking, and inactivity. Additionally, increasing spending on research and development of innovative nuclear therapies for the treatment of cancer may support segment expansion. As an illustration, the COMPOSE phase 3 trial of 177lu-edotreotide was launched by ITM Isotope Technologies Munich SE in January 2022 to assess the product’s potential for the treatment of patients with neuroendocrine tumours.
Frequently Asked Questions About This Report
How big is the nuclear medicine market?
What is the nuclear medicine market growth?
Which segment accounted for the largest nuclear medicine market share?
Who are the key companies/players in the nuclear medicine market?
What are the factors driving the nuclear medicine market?
